Â© Reuters. MAIA Biotechnology (MAIA) Costs 2.22 M Share IPO at $2.25/ sh
MAIA Biotechnology, Inc. (MAIA) today revealed the prices of an underwritten public offering of 2,222,200 shares of its typical stock at a public offering rate of $2.25 per share, for gross earnings of around $5 million, prior to subtracting underwriting discount rates and other offering costs. In addition, MAIA has actually given the underwriters a 45-day choice to buy as much as an extra 333,300 shares of typical stock to cover over-allotments at the general public offering rate, less the underwriting discount rate.
The Business means to utilize the net earnings to money the continuous medical trials of THIO, pre-clinical advancement of second-generation of telomere targeting substances, and other research study and advancement activities, along with for working capital and other basic business functions.
The offering is anticipated to close on April 27, 2023, based on fulfillment of popular closing conditions.
ThinkEquity is functioning as sole book-runner for the offering.
A registration declaration on Kind S-1 (File No. 333-269606) associating with the shares being offered was submitted with the Securities and Exchange Commission (” SEC”) and ended up being reliable on April 24, 2023. This offering is being made just by ways of a prospectus. Copies of the last prospectus, when offered, might be acquired from ThinkEquity, 17 State Street, 41st Flooring, New York City, New York City 10004, by telephone at (877) 436-3673, by e-mail at [email protected] The last prospectus will be submitted with the SEC and will be offered on the SEC’s site situated at https://www.sec.gov
This news release will not make up a deal to offer or a solicitation of a deal to purchase, nor will there be any sale of these securities in any state or jurisdiction in which such a deal, solicitation or sale would be illegal previous to registration or credentials under the securities laws of any such state or jurisdiction.
About MAIA Biotechnology, Inc.
MAIA is a targeted treatment, immuno-oncology business concentrated on the advancement and commercialization of possible first-in-class drugs with unique systems of action that are planned to meaningfully enhance and extend the lives of individuals with cancer. Its lead program is THIO, a prospective first-in-class cancer telomere targeting representative in medical advancement for the treatment of NSCLC clients with telomerase-positive cancer cells. To learn more, please go to www.maiabiotech.com
Forward Looking Declarations
MAIA warns that all declarations, besides declarations of historic truths, consisted of in this news release, are positive declarations. Positive declarations undergo recognized and unidentified threats, unpredictabilities, and other aspects that might trigger our or our market’s real outcomes, levels or activity, efficiency or accomplishments to be materially various from those expected by such declarations. Using words such as “may,” “might,” “will,” “should,” “could,” “anticipate,” “strategy,” “expect,” “think,” “price quote,” “task,” “plan,” “future,” “possible,” or “continue,” and other comparable expressions are planned to determine forward looking declarations. Nevertheless, the lack of these words does not suggest that declarations are not positive. For instance, all declarations we make concerning (i) the initiation, timing, expense, development and outcomes of our preclinical and medical research studies and our research study and advancement programs, (ii) our capability to advance item prospects into, and effectively total, medical research studies, (iii) the timing or probability of regulative filings and approvals, (iv) our capability to establish, make and advertise our item prospects and to enhance the production procedure, (v) the rate and degree of market approval of our item prospects, (vi) the size and development capacity of the marketplaces for our item prospects and our capability to serve those markets, and (vii) our expectations concerning our capability to get and preserve copyright defense for our item prospects, are forward looking. All positive declarations are based upon existing quotes, presumptions and expectations by our management that, although our company believe to be sensible, are naturally unsure. Any positive declaration revealing an expectation or belief regarding future occasions is revealed in great faith and thought to be sensible at the time such positive declaration is made. Nevertheless, these declarations are not warranties of future occasions and undergo threats and unpredictabilities and other aspects beyond our control that might trigger real outcomes to vary materially from those revealed in any positive declaration. Any positive declaration speaks just since the date on which it was made. We carry out no commitment to openly upgrade or modify any positive declaration, whether as an outcome of brand-new info, future occasions or otherwise, other than as needed by law. In this release, unless the context needs otherwise, “MAIA,” “Business,” “we,” “our,” and “us” describes MAIA Biotechnology, Inc. and its subsidiaries.
Chief Financial Officer
Source: MAIA Biotechnology, Inc.